Evaluation of the efficacy and safety of Xuefu Zhuyu oral liquid on patients with lupus nephritis and the effect of serum thymosin β4
Objective To investigate the clinical efficacy and safety of Xuefu Zhuyu oral liquid(XZOL)on patients with lupus nephritis(LN)and the effect of serum thymosin β4.Methods Patients treated in the Second Hospital Affiliated to Hebei North College from October 2021 to October 2022 were included in the study.Using the random number method,the LN patients were divided into the control group[prednisone(PDN)+cyclophosphamide(CTX)]and the blood-focused group(XZOL combined with PDN+CTX),and were treated continuously for 6 months.The two groups were compared in terms of treatment efficiency,systemic lupus erythematosus disease activity index(SLEDAI)score,immune indexes[anti-double-stranded DNA(dsDNA)antibody,serum immunoglobulin(Ig)G and serum complement C3 levels]and renal function indexes(Scr,ALB,ESR,ALT,24h urine protein and CRP levels),serum thymidine β4 levels and safety(incidence of adverse reactions).Results A total of 60 LN patients were included in the study,30 in each group.The total effective rate of treatment in the Xuefu Zhuyu group was significantly higher than that in the control group(P<0.05).Before treatment,there was no statistically significant difference in SLEDAI score,serum thymidine β4,IgG,C3,anti-dsDNA antibody,serum Scr,ALB,ALT,24 h urine protein and CRP levels between the two groups(P>0.05).After 6 months of treatment,SLEDAI score,serum IgG,anti-dsDNA antibody,serum Scr,ALT,24 h urine protein and CRP levels of patients in both groups decreased significantly compared with those before treatment(P<0.05),while serum thymosin β4 level,serum C3 level and serum ALB level increased significantly(P<0.05);the SSLEDAI score,serum IgG,anti-dsDNA antibody,serum Scr,ALT,24 h urine protein and CRP levels were lower in the Xuefu Zhuyu group than in the control group(P<0.05),and serum thymosin β4,C3 and ALB levels were higher than in the control group(P<0.05).In addition,there was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion XZOL is clinically effective in the treatment of LN,with fewer adverse reactions,and is worth promoting its use in the clinic.
万方数据
维普
